Commentary | Published:

Human genetics as a foundation for innovative drug development

Nature Biotechnology volume 31, pages 975978 (2013) | Download Citation

New technology has transformed human genetics. It now provides perhaps the single best opportunity to innovate and improve clinical success rates in drug development.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

References

  1. 1.

    Nature 276, 565–570 (1978).

  2. 2.

    & Nature 437, 491–493 (2005).

  3. 3.

    et al. Nat. Rev. Drug Discov. 9, 203–214 (2010).

  4. 4.

    & J. Clin. Oncol. 31, 1061–1069 (2013).

  5. 5.

    Wellcome Trust Case Control Consortium. Nature 447, 661–678 (2007).

  6. 6.

    et al. Sci. Transl. Med. 2, 62ra92 (2010).

  7. 7.

    & Med. Times 100, 173–175 (1972).

  8. 8.

    , , , & Am. J. Med. 62, 707–714 (1977).

  9. 9.

    The AIM-HIGH Investigators. N. Engl. J. Med. 365, 2255–2267 (2011).

  10. 10.

    et al. N. Engl. J. Med. 357, 2109–2122 (2007).

  11. 11.

    et al. N. Engl. J. Med. 367, 2089–2099 (2012).

  12. 12.

    et al. Lancet 380, 572–580 (2012).

  13. 13.

    et al. Nat. Genet. 37, 161–165 (2005).

  14. 14.

    et al. Am. J. Hum. Genet. 79, 514–523 (2006).

  15. 15.

    , , & Atherosclerosis 193, 445–448 (2007).

  16. 16.

    , , , & J. Lipid Res. 53, 2515–2524 (2012).

  17. 17.

    et al. J. Lipid Res. 40, 1113–1122 (1999).

  18. 18.

    et al. Nat. Genet. 34, 154–156 (2003).

  19. 19.

    , , & N. Engl. J. Med. 354, 1264–1272 (2006).

  20. 20.

    , , , & J. Am. Coll. Cardiol. 55, 2833–2842 (2010).

  21. 21.

    J. Am. Med. Assoc. 251, 351–364 (1984).

  22. 22.

    J. Am. Med. Assoc. 251, 365–374 (1984).

  23. 23.

    , & J. Am. Med. Assoc. 256, 2823–2828 (1986).

  24. 24.

    et al. N. Engl. J. Med. 322, 1700–1707 (1990).

  25. 25.

    , & Ann. Intern. Med. 115, 687–693 (1991).

  26. 26.

    , & N. Engl. J. Med. 323, 1112–1119 (1990).

  27. 27.

    et al. Circulation 97, 1837–1847 (1998).

  28. 28.

    , , & Lancet 353, 89–92 (1999).

  29. 29.

    et al. Circulation 110, 227–239 (2004).

  30. 30.

    et al. Heart 90, 1385–1391 (2004).

  31. 31.

    et al. N. Engl. J. Med. 352, 1425–1435 (2005).

  32. 32.

    , , , & J. Am. Coll. Cardiol. 48, 438–445 (2006).

  33. 33.

    Cholesterol Treatment Trialists', (CTT) Collaboration et al. Lancet 376, 1670–1681 (2010).

  34. 34.

    et al. Proc. Natl. Acad. Sci. USA 102, 5374–5379 (2005).

  35. 35.

    et al. J. Lipid Res. 48, 1488–1498 (2007).

  36. 36.

    & Arterioscler. Thromb. Vasc. Biol. 29, 431–438 (2009).

  37. 37.

    , & J. Lipid Res. 50 (suppl.), S172–S177 (2009).

  38. 38.

    & Proc. Natl. Acad. Sci. USA 106, 9546–9547 (2009).

  39. 39.

    , & in McKinsey Perspectives on Drug and Device R&D, 2–11 (2012).

  40. 40.

    et al. Nat. Genet. 43, 316–320 (2011).

Download references

Author information

Affiliations

  1. Alexander Kamb and Sean Harper are at Amgen, Thousand Oaks, California, USA

    • Alexander Kamb
    •  & Sean Harper
  2. Kari Stefansson is at deCODE Genetics/Amgen, Reykjavik, Iceland.

    • Kari Stefansson

Authors

  1. Search for Alexander Kamb in:

  2. Search for Sean Harper in:

  3. Search for Kari Stefansson in:

Competing interests

Authors employed by Amgen and deCODE.

Corresponding author

Correspondence to Alexander Kamb.

About this article

Publication history

Published

DOI

https://doi.org/10.1038/nbt.2732

Newsletter Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing